Christoph Thiemermann

机构：Queen Mary University of London, William Harvey Research Institute · ORCID：0000-0003-4228-9722

发表论文 687 篇 · 总被引 34048 次 · h-index 92

代表论文

• Spleen tyrosine kinase: a novel pharmacological target for sepsis-induced cardiac dysfunction and multi-organ failure (2024 · Frontiers in Immunology · 被引 9)
• OxPhos in adipose tissue macrophages regulated by BTK enhances their M2-like phenotype and confers a systemic immunometabolic benefit in obesity. (2024 · Diabetes · 被引 8)
• Targeting immunometabolic pathways with AZD1656 alleviates inflammation and metabolic dysfunction in type 2 diabetic cardiomyopathy (2026 · Nature Cardiovascular Research · 被引 4)
• Correction: RG100204, a novel Aquaporin-9 inhibitor, reduces septic cardiomyopathy and multiple organ failure in murine sepsis (2025 · Frontiers in Immunology · 被引 1)
• Correction to: IkB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD (2026 · Journal of the American Society of Nephrology)
• RETRACTED: “Evidence for the Role of Peroxisome Proliferator-Activated Receptor- β/δ in the Development of Spinal Cord Injury” (2026 · Journal of Pharmacology and Experimental Therapeutics)